Infrared Photobiomodulation in Humans With Epilepsy
Recruiting · NCT07145489 · Interventional (participants receive a specific treatment) · Lead sponsor: Beth Israel Deaconess Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
photobiomodulation
What this trial is about
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Drug resistant epilepsy
- Age 18 or older
- Average seizure rate of at least 2 seizures per month
- Accurate seizure diary with at least 3 months recorded
Exclusion criteria
- Implanted intracranial neurostimulation device (DBS or RNS)
- Intracranial shunt
- Skin photosensitivity
- Cancer on scalp
- Taking any medication that can cause photosensitivity
Where it is running
1 location listed across 1 US state.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →